Tags : Linnaeus

PharmaShots Weekly Snapshot (Oct 12-16, 2020)

Tuba Khan October 16, 2020

Novartis’s Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Retinal Disease Published: Oct 15, 2020 | Tags: approval, Canada, health, Inherited Retinal Disease, […]readmore

Clinical Trials

Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab)

Tuba Khan October 14, 2020

Shots: The first patient has been dosed in P-l/ll adaptive-design study assessing the safety, tolerability, pharmacokinetics, and antitumor activity of LNS8801+ Keytruda (pembrolizumab) in patients who had previous clinical benefit […]readmore

Tags : Linnaeus

PharmaShots Weekly Snapshot (Oct 12-16, 2020)

Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Linnaeus

PharmaShots Weekly Snapshot (Oct 12-16, 2020)

Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company